Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma
Recruiting now · Phase 1
Conditions studied: T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma
In brief
The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma. Participants will: * have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory. * be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells. * be given the CAR T cells into their vein. * stay in the hospital for a minimum of 2 weeks to be closely monitored * following discharge, participants will come to the clinic for check-ups (approximately 12 visits in the first two years) * during screening, treatment and follow up visits, participants will have physical examination, collection of blood samples and bone marrow biopsies and/or imaging tests (CT/PET-CT scans) depending on their type of T-cell cancer.
Key facts
- Study ID
- NCT07300683
- Run by
- University College, London
- People needed
- 24
- Starts
- 2025-11-11
- Expected to finish
- 2042-12-01
- Last updated by the study team
- 2025-12-24
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University College London Hospitals — London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.